KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Cash from Operations (2016 - 2025)

Boston Scientific's Cash from Operations history spans 17 years, with the latest figure at 1364000000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 6.32% year-over-year to 1364000000.0; the TTM value through Dec 2025 reached 4534000000.0, up 31.99%, while the annual FY2025 figure was 4534000000.0, 31.99% up from the prior year.
  • Cash from Operations for Q4 2025 was 1364000000.0 at Boston Scientific, up from 1343000000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1456000000.0 in Q4 2024 and bottomed at 58000000.0 in Q1 2022.
  • The 5-year median for Cash from Operations is 650500000.0 (2021), against an average of 693400000.0.
  • The largest annual shift saw Cash from Operations surged 468.83% in 2021 before it plummeted 120.42% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 478000000.0 in 2021, then surged by 68.83% to 807000000.0 in 2022, then rose by 18.59% to 957000000.0 in 2023, then surged by 52.14% to 1456000000.0 in 2024, then dropped by 6.32% to 1364000000.0 in 2025.
  • Per Business Quant, the three most recent readings for BSX's Cash from Operations are 1364000000.0 (Q4 2025), 1343000000.0 (Q3 2025), and 1286000000.0 (Q2 2025).